Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme.
Journal: Journal of Crohn's & colitis
Published: March 13, 2024
Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies.
Journal: Intestinal research
Published: September 19, 2023
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Journal: The New England journal of medicine
Published: June 28, 2023
Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52.
Journal: Clinical and translational gastroenterology
Published: April 07, 2023
A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials.
Journal: Drug safety
Published: May 09, 2018
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.
Journal: Clinical pharmacokinetics
Published: May 20, 2017
Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
Journal: Drugs in R&D
Published: December 23, 2015
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Journal: Gut
Published: November 11, 2015
Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Journal: International journal of clinical pharmacology and therapeutics
Published: June 16, 2015
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Journal: Gastroenterology
Published: December 20, 2013
Vedolizumab as induction and maintenance therapy for Crohn's disease.
Journal: The New England journal of medicine
Published: August 23, 2013
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Journal: The New England journal of medicine
Published: August 23, 2013
Last Updated: 09/26/2026